Narayanan Suresh

Chief Operating Officer
ABLE (Association of Biotechnology Led Enterprises)
 

Narayanan Suresh is the Chief Operating Officer of India’s Biotech Industry Association, ABLE, the Association for Biotechnology-Led Enterprises. In this role, Suresh represents the interests of 350-strong membership that has contributed to the emergence of a $63 billion (Rs 460,000 crore) BioEconomy in India. ABLE runs pioneering programs like BEST to promote entrepreneurship among biotech students, engages with governments on policy and regulatory issues, provides a platform for national and international biotech sector to interact on a range of issues, runs the BioEconomy Conclave Series of events. ABLE also produces the annual India BioEconomy Report (IBER) and India Biotech Startups Dashboard. 

Prior to this, Suresh was the Group Editor of BioSpectrum, Asia’s first exclusive BioScience magazine, published simultaneously from India and Singapore. Published in print and available online and in fortnightly digital versions, BioSpectrum is Asia’s No.1 media platform that engages the BioScience industry. 

Suresh was also the editor of the India Edition of MIT’s Technology Review magazine which highlighted technological innovations in India and also produced an annual list of young technology innovators under the age of 35. 

He started BioSpectrum for CyberMedia and has played a key role in catalyzing the growth of this much talked about industry in India and Asia-Pacific. The magazine also brings out widely acclaimed annual ranking of BioScience companies in Asia-Pacific and Top 20 Biotech companies in India every June. BioSpectrum also pioneered industry awards in the region with the annual BioSpectrum Awards in Bangalore and Singapore to honor outstanding personalities in the bioscience segment. A Masters in Physics from the Central University of Hyderabad Suresh started his career as the first Science Correspondent of The Times of India, New Delhi.

Speech title & Synopsis

Regional Collaboration Forum: INDIA- A Reliable Partner for the World

During the Covid pandemic years, India’s biotech companies demonstrated global leadership by producing over 2 billion doses of various COVID-19 vaccines and adding to the availability to vulnerable countries without vaccine manufacturing capabilities through the Covax program.

Biotechnology research and development is a complex, long gestation and resource intensive process. Also, innovation and speed are essential and companies seek to de-risk development and manufacturing costs by using competent partners around the world. India’s biotechnology companies are filling the global need for Contract Development and Manufacturing Organizations (CDMOs) for a wide range of biopharma products. India’s biotech CDMOs are emerging as reliable partners to help the global pharmaceutical industry with their specialized expertise in manufacturing and various steps involved in the entire value chain as affordable and reliable partners to lower the risk of capital deployment.

This session will show case FOUR such companies from India that offer, with their integrated facilities across the biotech/pharma value chain, a wide range of development and manufacturing capabilities as reliable partners to the global pharmaceutical industry.